12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Phase II started

Seattle Genetics began an open-label, U.S. Phase II trial to evaluate Adcetris as monotherapy in about 20 newly diagnosed Hodgkin's lymphoma patients ages >=60 years. Adcetris has accelerated approval in the U.S. to treat Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). In July, EMA's CHMP recommended conditional approval of an MAA from Takeda...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >